LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Company Overview - LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop to improve near vision in people with presbyopia [3] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine [3] - The company is headquartered in San Diego, California [3] Market Potential - Presbyopia affects an estimated 1.8 billion people globally and 128 million people in the United States [3] - LENZ Therapeutics aims to provide an ideal pharmaceutical solution for presbyopia that enhances vision for "all eyes, all day" [3] Regulatory Milestones - The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [3] Upcoming Events - The company will host a webcast on May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights [1]